Hypofractionation for Postprostatectomy Radiotherapy
Mené sur 296 patients atteints d'un cancer de la prostate et ayant subi une prostatectomie (âge médian : 65 ans), cet essai randomisé international de phase III évalue la non-infériorité, du point de vue des évènements indésirables génito-urinaires et gastro-intestinaux rapportés par les patients après 2 ans et évalués à l'aide d'un système de score, d'une radiothérapie post-prostatectomie hypofractionnée par rapport à une radiothérapie post-prostatectomie conventionnellement fractionnée
Hypofractionation for prostate radiotherapy is well established, with international guidelines supporting the use of moderately hypofractionated radiotherapy for patients who choose external beam radiotherapy for treatment of prostate cancer. Hypofractionated radiotherapy enables better convenience for patients and cost benefits and, in comparison with conventional fractionation, has similar cancer-related outcomes and late gastrointestinal (GI) and genitourinary (GU) adverse effects. Long-term data regarding the effect on quality of life with moderate hypofractionation shows similar prevalence of overall bowel, urinary, and sexual problems compared with conventional fractionation. Additionally, patient-reported outcomes for bowel and urinary problems showed little change between 6 months and 5 years.
JAMA Oncology 2024